YCYves Carlier

Yves Carlier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yves Carlier has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trypanosoma cruzi infection in pregnancy: New approaches to address the diagnosis and follow-up of women and newborns

    by Yves Carlier, Jackeline Alger, Eric Dumonteil, Claudia Herrera, Alejandro G. Schijman, Pierre Buekens

    The transplacental route is the main human-to-human transmission mode of Trypanosoma cruzi infection, causing congenital Chagas disease, a major health problem in most endemic and nonendemic areas. The prevention, diagnosis, and follow-up of pregnant women and congenitally infected newborns face limitations, such as regional variations of concordance among serological tests used to diagnose T. cruzi infection in the Americas, the low sensitivity of microscopic examination for detecting live trypomastigotes in blood, and losses of infected women and newborns in screening and follow-up programs. In addition, fetal growth retardation was recently documented in uninfected newborns of infected mothers. The potential practical impacts of some new approaches, based on fundamental concepts and results of clinical observations addressing T. cruzi infection in pregnancy, such as simplifying the serodiagnosis, detecting and identifying live T. cruzi clones and monitoring fetal growth retardation in all neonates of infected mothers, are discussed as open research questions.

  • Coinfection by multiple Trypanosoma cruzi clones: a new perspective on host-parasite relationship with consequences for pathogenesis and management of Chagas disease

    by Yves Carlier, Eric Dumonteil, Claudia Herrera, Etienne Waleckx, Michel Tibayrenc, Pierre Buekens, Carine Truyens, Eric Muraille

    SUMMARY: Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi (Tc), infecting 6–7 million people. It is transmitted by insect vectors, orally, through infected tissues, or congenitally. Tc infection can progress toward chronic cardiac and/or digestive severe and fatal CD in 20%–40% of patients. Tc exhibits an important genetic and phenotypic intraspecies diversity and a preponderant clonal population structure. The impact of multiclonal coinfections has been little studied in CD patients. Relationships between the currently used discrete typing unit (DTU)-based classification of Tc lineages and the occurrence of the different clinical forms of CD, its congenital transmission, as well as the efficacy of trypanocidal molecules (benznidazole and nifurtimox) could not be established. In this review, we revisit the different aspects of Tc diversity and analyze the impact of infections with multiple clones and their variants on the dynamic and pathogenesis of CD and its maternal-fetal transmission. We propose to call “cruziome” all the Tc clones and their variants infecting a given host and provide strong evidence that (i) multiclonal Tc infections are likely the rule rather than the exception; (ii) each “cruziome” is associated with a unique combination of virulence factors, tissular tropisms, and host immune responses; (iii) accordingly, some particularly harmful “cruziomes” likely trigger the occurrence and progression of CD and might also favor the congenital transmission of parasites. We propose that our concept of “cruziome” should be taken into consideration because of its practical consequences in epidemiological studies, laboratory diagnosis, clinical management, and treatment of CD.


  • Trypanosoma cruzi Infection in Pregnancies without Congenital Transmission Is Associated with Reduced Fetal Growth: A Cross-Sectional Study in Argentina, Honduras, and Mexico

    by Angel Paternina-Caicedo, Jackeline Alger, Maria Luisa Cafferata, Yves Carlier, Eric Dumonteil, Luz Gibbons, Tamara Hammerman, Claudia Herrera, Pierre Buekens

    We aimed to measure the association between Trypanosoma cruzi infection in pregnancy and reduced fetal growth in the absence of T. cruzi congenital transmission. We conducted a cross-sectional study of secondary data of all singleton live births between 2011 and 2013 in five hospitals from Argentina, Honduras, and Mexico. We excluded newborns with T. cruzi infection. Noninfected pregnant people were those without any positive rapid tests. The main study outcomes were birth weight, head circumference, and length for gestational age and sex. Logistic regression models were adjusted for country, age, education level, and obstetric history. Of the 26,544 deliveries, 459 (1.7%) pregnant people were found by rapid tests to be positive for T. cruzi. Of these, 320 were positive by enzyme-linked immunosorbent assay and 231 had a positive polymerase chain reaction (PCR) test. Uninfected newborns from T. cruzi-infected pregnant people were more likely to have birth weights below the 5th and 10th percentiles and head circumferences below the 3rd and 10th percentiles. Among T. cruzi-infected pregnant people diagnosed by PCR, the odds ratios were 1.58 for birth weight below the 10th percentile (95% CI, 1.12–2.23) and 1.57 for birth weight below the 5th percentile (95% CI, 1.02–2.42). Higher T. cruzi parasitic loads in pregnancy had a stronger association with reduced fetal growth (both in birth weight and head circumference), with an odds ratio of 2.31 (95% CI, 1.36–3.91) for a birth weight below the 5th percentile. The association shows, irrespective of causality, that newborns of pregnancies with T. cruzi have an increased risk of reduced fetal growth. We recommend further studies to assess other potential confounders and the causality of these associations.


  • Open Access

    Case report: strong lung reaction to the BNT162b2 mRNA vaccine applied one month after a pulmonary form of covid-19

    by Alejandra Aguilar Robles, Yves Carlier

    This case report documents a reactivation of a pulmonary pathology, beginning some hours after the administration of a first dose of BNT162b2 mRNA vaccine, in a patient having presented a symptomatic pulmonary form of covid-19 one month before. The lessons to be learned and the possible involved mechanisms are discussed.

  • Open Access

    Monocytes from Uninfected Neonates Born to Trypanosoma cruzi-Infected Mothers Display Upregulated Capacity to Produce TNF-α and to Control Infection in Association with Maternally Transferred Antibodies

    by Amilcar Flores, Cristina Alonso-Vega, Emmanuel Hermann, Mary-Cruz Torrico, Nair Alaide Montaño Villarroel, Faustino Torrico, Yves Carlier, Carine Truyens

    Activated monocytes/macrophages that produce inflammatory cytokines and nitric oxide are crucial for controlling Trypanosoma cruzi infection. We previously showed that uninfected newborns from T. cruzi infected mothers (M+B- newborns) were sensitized to produce higher levels of inflammatory cytokines than newborns from uninfected mothers (M-B- newborns), suggesting that their monocytes were more activated. Thus, we wondered whether these cells might help limit congenital infection. We investigated this possibility by studying the activation status of M+B- cord blood monocytes and their ability to control T. cruzi in vitro infection. We showed that M+B- monocytes have an upregulated capacity to produce the inflammatory cytokine TNF-α and a better ability to control T. cruzi infection than M-B- monocytes. Our study also showed that T. cruzi-specific Abs transferred from the mother play a dual role by favoring trypomastigote entry into M+B- monocytes and inhibiting intracellular amastigote multiplication. These results support the possibility that some M+B- fetuses may eliminate the parasite transmitted in utero from their mothers, thus being uninfected at birth.


  • Open Access

    Is Antibody-Dependent Enhancement of Trypanosoma cruzi Infection Contributing to Congenital/Neonatal Chagas Disease?

    by Yves Carlier, Carine Truyens, Eric Muraille

    The newborns of women infected with the parasite Trypanosoma cruzi (the agent of Chagas disease) can be infected either before birth (congenitally), or after birth (as e.g., by vector route). Congenital Chagas disease can induce high levels of neonatal morbidity and mortality. Parasite-infected pregnant women transmit antibodies to their fetus. Antibodies, by opsonizing parasites, can promote phagocytosis and killing of T. cruzi by cells expressing FcγR, on the mandatory condition that such cells are sufficiently activated in an inflammatory context. Antibody-dependent enhancement (ADE) is a mechanism well described in viral infections, by which antibodies enhance entry of infectious agents into host cells by exploiting the phagocytic FcγR pathway. Previously reported Chagas disease studies highlighted a severe reduction of the maternal-fetal/neonatal inflammatory context in parasite-transmitting pregnant women and their congenitally infected newborns. Otherwise, experimental observations brought to light ADE of T. cruzi infection (involving FcγR) in mouse pups displaying maternally transferred antibodies, out of an inflammatory context. Herein, based on such data, we discuss the previously unconsidered possibility of a role of ADE in the trans-placental parasite transmission, and/or the development of severe and mortal clinical forms of congenital/neonatal Chagas disease in newborns of T. cruzi-infected mothers.


  • Placenta, Trypanosoma cruzi, and Congenital Chagas Disease

    by Yves Carlier, Alejandro G. Schijman, Ulrike Kemmerling


  • Open Access

    Congenital Chagas disease: Updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of childbearing age, and pregnant women

    by Yves Carlier, Jaime Altcheh, Andrea Angheben, Hector Freilij, Alejandro O Luquetti, Alejandro G Schijman, Manuel Segovia, Noemie Wagner, Pedro Albajar Vinas


  • Congenital Transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: An Observational Prospective Study

    by Pierre Buekens, Maria-Luisa Cafferata, Jackeline Alger, Fernando Althabe, Jose M. Belizan, Norma Bustamante, Yves Carlier, Alvaro Ciganda, Jaime H. DelCid, Eric Dumonteil, et al.

    Compared with South America, there is a lack of epidemiologic studies about the risk of congenital transmission of Trypanosoma cruzi in Central America and Mexico. It has been suggested that T. cruzi genotypes might differ by region and that congenital transmission might vary according to the parasite’s genotype. Our objective was to compare T. cruzi congenital transmission rates in three countries. We performed an observational prospective study in 2011–2014 enrolling women at delivery in one hospital in Argentina, two hospitals in Honduras, and two hospitals in Mexico. Congenital T. cruzi infection was defined as the presence of one or more of the following criteria: presence of parasites in cord blood (direct parasitological microscopic examination) with positive polymerase chain reaction (PCR) in cord blood, presence of parasites in infant’s blood at 4–8 weeks (direct parasitological microscopic examination), and persistence of T. cruzi-specific antibodies at 10 months, as measured by at least two tests. Among 28,145 enrolled women, 347 had at least one antibody rapid test positive in cord blood and a positive enzyme-linked immunosorbent assay in maternal blood. PCR in maternal blood was positive in 73.2% of the cases, and genotyping identified a majority of non-TcI in the three countries. We found no (0.0%; 95% confidence interval [CI]: 0.0, 2.0) confirmed congenital case in Honduras. Congenital transmission was 6.6% (95% CI: 3.1, 12.2) in Argentina and 6.3% (95% CI: 0.8, 20.8) in Mexico. Trypanosoma cruzi non-TcI predominated and risks of congenital transmission were similar in Argentina and Mexico.